KY-02327

SKU: orb1303525

Description

KY-02327 is a metabolically stabilized small molecule that potently inhibits the Dishevelled-CXXC5 protein interaction. This inhibition activates the Wnt/β-catenin signaling pathway, which has been shown in research to stimulate osteoblast differentiation in vitro, making it a useful tool for studying bone formation and regeneration.

Research Area

Signal Transduction, Stem Cell & Developmental Biology

Key Properties

• CAS Number: 2093407-25-9
• MW: 373.45
• Purity: 97.04% (May vary between batches)
• Formula: C₂₀H₂₇N₃O₄
• SMILES: C(C(NCCN1CCCCC1)=O)N2C=3C(C=C2C(OCC)=O)=CC(O)=CC3
• Target: Others,Wnt/beta-catenin
• Solubility: DMSO:100 mg/mL (267.77 mM);10% DMSO+40% PEG300+5% Tween 80+45% Saline:4 mg/mL (10.71 mM)

Bioactivity

• In Vivo:
  KY-02327 (20 mg/kg; p.o.; administered for 5 consecutive days each week for 4 weeks) effectively mitigates bone loss in an ovariectomized (OVX) mouse model, demonstrating its potential for osteoporosis treatment by stimulating bone growth. In this study, 8-week-old female BL6 mice were treated following the specified regimen, resulting in increased bone formation in the femur, confirmed by calcein labeling, compared to vehicle-treated OVX mice.
  Read more...
• In Vitro:
  KY-02327 treatment (1-10 μM; 2 days) on MC3T3E1 cells, a murine pre-osteoblast cell line, enhances β-catenin protein level and Runx2, as well as nuclear β-catenin accumulation, in a dose-dependent manner . Additionally, KY-02327 (1-10 μM) elevates the mRNA expression of osteoblast differentiation markers, collagen 1a (Col1a) and osteocalcin (OCN) .
  Read more...

Storage & Handling

• Storage: -20°C
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

Wnt, anabolic, anti-osteoporosis, bone, differentiation, Dishevelled, CXXC5-DVL, CXXC5, Inhibitor, osteoblast, inhibit, KY02327, KY-02327, KY 02327

Compound Identifiers

PubChem CID

142737047